Drägerwerk AG & Co. KGaA/€DRW8

06:30
10:10
13:45
17:25
21:00
1D1W1MYTD1Y5YMAX

About Drägerwerk AG & Co. KGaA

Drägerwerk AG & Co. KGaA is a German company specializing in medical and safety technology. The company provides a range of products and solutions in the fields of critical care, which includes anesthesia workstations, ventilators, and patient monitoring, as well as safety products for personal protection, gas detection, and firefighting. Dräger was founded in 1889 and is headquartered in Lübeck, Germany. Its operations extend globally, serving various industries such as healthcare, emergency services, mining, and industrial applications. Drägerwerk's strategic strength lies in its focus on high-quality, technologically advanced products and its long-standing expertise in medical and safety technologies.

Ticker

€DRW8
Sector

Primary listing

XETRA

Employees

16,684

DRW8 Metrics

BasicAdvanced
€1.2B
-
-
0.39
€1.97
3.23%

Bulls say / Bears say

In FY 2024, Drägerwerk delivered a 16.6% increase in EBIT to €194.0 million and improved its margin to 5.8%, enabling a dividend hike to €1.97 per common share and reinforcing its cash-return policy (EQS News).
Q1 2025 saw order intake rise 6.1% year-on-year to €861 million—Dräger’s strongest first quarter since 2020—driven by robust demand across both medical and safety divisions (EQS Ad-hoc).
In H1 2025, order intake surged 10.1% to €1,738.0 million, the highest half-year level since 2020, with the Americas region up ~25% and strong contributions from both divisions, setting the stage for potential second-half sales growth (TradingView).
Q1 2025 EBIT plunged to just €0.4 million from €15.1 million a year earlier, translating into a razor-thin 0.1% margin as rising personnel and other expenses eroded profitability despite stable sales (EQS Ad-hoc).
In H1 2025, EBIT fell to €20.4 million versus €55.8 million in H1 2024, mainly due to the absence of prior-year one-off gains and negative currency and customs effects, highlighting ongoing earnings pressure at base levels (FinanzWire).
Medical division net sales declined by 3.4% in FY 2024 to €1,899.7 million (2023: €1,966.2 million) and Asia-Pacific sales fell 10.9%, underscoring regional demand weakness that could dampen future growth (FinanzWire).
Data summarised monthly by Lightyear AI. Last updated on 9 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €DRW8

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs